Two new drug approvals (for patients with EGFR Exon 20 insertion and patients with KRAS G12C mutation)
The FDA based their approval on the results of the clinical trial CHRYSALIS which showed that patients receiving Rybrevant responded to the drug for a year.
In addition to approving Rybrevant, the FDA also granted approval for Guardant360 CDx as a companion diagnostic.
The FDA based their approval on the results of the clinical trial CHRYSALIS which showed that patients receiving Rybrevant responded to the drug for a year.
In addition to approving Rybrevant, the FDA also granted approval for Guardant360 CDx as a companion diagnostic.
